Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

BACKGROUND: Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. METHODS: Patients with primary triple negative breast cancer ≥2 cm received doxor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Di Cosimo, Serena, La Verde, Nicla, Moretti, Anna, Cazzaniga, Marina Elena, Generali, Daniele, Bianchi, Giulia Valeria, Mariani, Luigi, Torri, Valter, Crippa, Flavio, Paolini, Biagio, Scaperrotta, Gianfranco, De Santis, Maria Carmen, Di Nicola, Massimo, Apolone, Giovanni, Gulino, Alessandro, Tripodo, Claudio, Colombo, Mario Paolo, Folli, Secondo, de Braud, Filippo
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2019
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6685628/
https://ncbi.nlm.nih.gov/pubmed/31390375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0220644
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items